First-line trial of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene - Phase II trial.

Trial Profile

First-line trial of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene - Phase II trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gefitinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
    • 25 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 02 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top